RXDX Right, once priced, I tried for $6.35, but it didn't come close. Though patience may yet reward me there. So far, behaving in marked contrast to other recent bio-secondaries. CARA and MGNX come to mind. I got a lucky spike and bailed my CARA trading shares for dinner money, having bought the post announcement pre-pricing weakness. Since then, I've been selling puts on it, and am a bit under water, wondering why it's behaving so much worse than RXDX and MGNX, since all three haven't had other significant news to explain the difference.
Cheers, Tuck |
